📣 VC round data is live. Check it out!

Century Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Century Therapeutics and similar public comparables like Invivyd, Recbio, CytoDyn, TaiMed Biologics and more.

Century Therapeutics Overview

About Century Therapeutics

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.


Founded

2018

HQ

United States

Employees

150

Financials (LTM)

Revenue: $72M
Net Income: ($40M)

EV

$339M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Century Therapeutics Financials

Century Therapeutics reported last 12-month revenue of $72M.

In the same LTM period, Century Therapeutics generated $72M in gross profit and had net loss of ($40M).

Revenue (LTM)


Century Therapeutics P&L

In the most recent fiscal year, Century Therapeutics reported revenue of $109M and EBITDA of $3M.

Century Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of 2% and net margin of (9%).

See analyst estimates for Century Therapeutics
LTMLast FY202320242025202620272028
Revenue$72M$109M$2M$7M$109M
Gross Profit$72M
Gross Margin100%
EBITDA$3M($121M)($111M)$3M
EBITDA Margin2%(5423%)(1692%)2%
EBIT Margin(67%)(10%)(5601%)(2031%)(10%)
Net Profit($40M)($10M)($137M)($127M)($10M)
Net Margin(56%)(9%)(6115%)(1921%)(9%)

Financial data powered by Morningstar, Inc.

Century Therapeutics Stock Performance

Century Therapeutics has current market cap of $413M, and enterprise value of $339M.

Market Cap Evolution


Century Therapeutics' stock price is $2.29.

Century Therapeutics share price increased by 331.7% in the last year.

Century Therapeutics has an EPS (earnings per share) of $-0.05.

See more trading valuation data for Century Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$339M$413M-0.9%0.0%102.9%331.7%$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Century Therapeutics Valuation Multiples

Century Therapeutics trades at 4.7x EV/Revenue multiple, and 130.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Century Therapeutics

EV / Revenue (LTM)


Century Therapeutics Financial Valuation Multiples

As of May 5, 2026, Century Therapeutics has market cap of $413M and EV of $339M.

Century Therapeutics has a P/E ratio of (10.3x).

LTMLast FY202320242025202620272028
EV/Revenue4.7x3.1x151.9x51.5x3.1x
EV/EBITDA130.8x(2.8x)(3.0x)130.8x
EV/EBIT(7.1x)(32.3x)(2.7x)(2.5x)(32.3x)
EV/Gross Profit4.7x
P/E(10.3x)(43.1x)(3.0x)(3.3x)(43.1x)
EV/FCF(3.2x)(3.3x)(3.1x)(3.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Century Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Century Therapeutics Margins & Growth Rates

In the most recent fiscal year, Century Therapeutics reported EBITDA margin of 2% and net margin of (9%).

See estimated margins and future growth rates for Century Therapeutics

Century Therapeutics Margins

Last FY20242025202720282029
EBITDA Margin2%(1692%)2%
EBIT Margin(10%)(2031%)(10%)
Net Margin(9%)(1921%)(9%)
FCF Margin(96%)(1674%)(96%)

Century Therapeutics Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth195%1557%
EBITDA Growth(8%)(102%)
EBIT Growth7%(92%)
Net Profit Growth(7%)(92%)
FCF Growth8%(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Century Therapeutics Operational KPIs

Century Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Century Therapeutics
LTMLast FY202320242025202620272028
Revenue per Employee$0.7M
Opex per Employee$0.8M
G&A Expenses to Revenue31%22%1553%503%22%
R&D Expenses to Revenue127%88%4148%1628%88%
Opex to Revenue110%5701%2131%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Century Therapeutics Competitors

Century Therapeutics competitors include Invivyd, Recbio, CytoDyn, TaiMed Biologics, Benitec Biopharma, Ever Supreme Bio Technology, Autolus Therapeutics, Nika Pharmaceuticals, Neumora Therapeutics and Akebia Therapeutics.

Most Century Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Invivyd3.6x3.0x(3.6x)(2.8x)
Recbio245.0x247.2x(6.5x)
CytoDyn49.8x
TaiMed Biologics19.4x18.9x(3435.1x)
Benitec Biopharma(5.6x)
Ever Supreme Bio Technology12.2x12.0x22.7x
Autolus Therapeutics2.5x2.0x(0.8x)(0.8x)
Nika Pharmaceuticals(5512.1x)

This data is available for Pro users. Sign up to see all Century Therapeutics competitors and their valuation data.

Start Free Trial

Century Therapeutics Funding History

Before going public, Century Therapeutics raised $410M in total equity funding, across 2 rounds.


Century Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Series CAvidity Partners; Casdin Capital; Federated Kaufmann Fund; Fidelity; Leaps by Bayer; Logos Capital; Marshall Wace; Octagon Capital Advisors; OrbiMed; Qatar Investment Authority; RA Capital Management; Versant Ventures$160MCentury Therapeutics raised $160 million in a Series C funding round in March 2021, led by Casdin Capital. The investors included Avidity Partners, Casdin Capital, Federated Kaufmann Fund, Fidelity, Leaps by Bayer, Logos Capital, Marshall Wace, Octagon Capital Advisors, OrbiMed, Qatar Investment Authority, RA Capital Management, and Versant Ventures, among others. This brought the company's total funding to $410 million at that point. The company focuses on developing iPSC-derived cell therapies, particularly natural killer cell therapies for blood cancers and autoimmune diseases like lupus. Century Therapeutics went public in 2021 via a SPAC merger and has since faced challenges, including leadership changes, staff cuts, and pipeline reorganization. The Series C funding supported its early-stage pipeline development in allogeneic cell therapies. Subsequent developments include a $60 million private placement in 2024 led by Bain Capital Life Sciences to extend runway into 2026 and a $35 million acquisition of Clade Therapeutics for additional autoimmune programs. Recent PIPE financing of $135 million occurred in January 2026.
Jul-19Series AFujifilm; Leaps by Bayer; Versant Ventures$250MCentury Therapeutics, a Philadelphia-based biotechnology company, launched from stealth mode on July 1, 2019, with $250 million in Series A financing to develop allogeneic cell therapies using induced pluripotent stem cells (iPSCs) for hematologic and solid malignancies. The company harnesses adult stem cells to create genetically engineered iPSC-derived immune effector cells, such as NK and T cells, designed as off-the-shelf treatments targeting cancer. Founded by Versant Ventures in 2018, Century had previously partnered with Fujifilm Cellular Dynamics Inc. (FCDI), a specialist in iPSC manufacturing, to leverage genome integration-free reprogramming for GMP-grade lines. The financing round was led by Leaps by Bayer, Bayer's venture arm, which committed $215 million, with participation from Versant Ventures and FCDI. This substantial early funding positioned Century as a leader in next-generation cell therapies, differentiating from autologous approaches by enabling scalable production from donor-derived cells. Proceeds were allocated to advance multiple programs into clinical stages, accelerate platform development, and address high unmet needs in cancer immunotherapy. Leaps by Bayer highlighted the platform's potential for previously incurable cancers, aligning with their focus on paradigm-shifting life sciences innovations. Versant emphasized allogeneic reagents as the next wave in cell therapy for broader patient access.

Century Therapeutics M&A Activity

Century Therapeutics has acquired 2 companies to date.

Last acquisition by Century Therapeutics was on April 11th 2024. Century Therapeutics acquired Clade Therapeutics for $35M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Century Therapeutics

Clade Therapeutics
Empirica Therapeutics
Description
Clade Therapeutics is a Cambridge, Massachusetts-headquartered biopharmaceutical company founded in 2020 that engineers off-the-shelf stem cell therapies targeting autoimmune diseases and oncology. Its proprietary platform induces regulatory T cells and modifies hematopoietic stem cells for conditions like multiple sclerosis and lupus. Backed by ARCH Venture Partners and Takeda, Clade advances preclinical candidates toward IND filings at facilities in Kendall Square.
Empirica Therapeutics is a San Diego-based developer of adoptive cell therapies targeting glioblastoma and brain metastases. The company engineers allogeneic NK cells expressing chimeric receptors against solid tumor antigens like EGFRvIII. Empirica advances its lead candidate EMP-201 through Phase 1 trials in collaboration with academic centers.
HQ CountryUnited StatesCanada
HQ City
Deal Date11 Apr 202423 Jun 2020
Valuation$35Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Century Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Century Therapeutics

When was Century Therapeutics founded?Century Therapeutics was founded in 2018.
Where is Century Therapeutics headquartered?Century Therapeutics is headquartered in United States.
How many employees does Century Therapeutics have?As of today, Century Therapeutics has over 150 employees.
Who is the CEO of Century Therapeutics?Century Therapeutics' CEO is Brent Pfeiffenberger.
Is Century Therapeutics publicly listed?Yes, Century Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Century Therapeutics?Century Therapeutics trades under IPSC ticker.
When did Century Therapeutics go public?Century Therapeutics went public in 2021.
Who are competitors of Century Therapeutics?Century Therapeutics main competitors include Invivyd, Recbio, CytoDyn, TaiMed Biologics, Benitec Biopharma, Ever Supreme Bio Technology, Autolus Therapeutics, Nika Pharmaceuticals, Neumora Therapeutics, Akebia Therapeutics.
What is the current market cap of Century Therapeutics?Century Therapeutics' current market cap is $413M.
What is the current revenue of Century Therapeutics?Century Therapeutics' last 12 months revenue is $72M.
What is the current revenue growth of Century Therapeutics?Century Therapeutics revenue growth (NTM/LTM) is (100%).
What is the current EV/Revenue multiple of Century Therapeutics?Current revenue multiple of Century Therapeutics is 4.7x.
Is Century Therapeutics profitable?No, Century Therapeutics is not profitable.
What is the current net income of Century Therapeutics?Century Therapeutics' last 12 months net income is ($40M).
How many companies Century Therapeutics has acquired to date?As of May 2026, Century Therapeutics has acquired 2 companies.
What was the largest acquisition by Century Therapeutics?$35M acquisition of Clade Therapeutics on 11th April 2024 was the largest M&A Century Therapeutics has done to date.
What companies Century Therapeutics acquired?Century Therapeutics acquired Clade Therapeutics and Empirica Therapeutics.
In how many companies Century Therapeutics has invested to date?Century Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Century Therapeutics

Lists including Century Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial